Wednesday, 5 August 2020

Download our All Government Jobs Android app to get updates on your mobile.
05 August 2020 Current Affairs:Drug major Lupin announced the launch of its Favipiravir drug under the brand name ‘Covihalt.‘ The drug will be used to treat patients with mild to moderate COVID-19 symptoms at Rs.49.  The Drug Controller General of India (DCGI) has approved Favipiravir for emergency use. 

Highlights:
♦ The Covihalt dosage strength has been developed keeping in mind the convenience of administration.
♦ The drug will be available as 200 mg tablets in the form of a strip of 10 tablets and priced at Rs.49 per tablet.
♦ The aim is to leverage the expertise in managing widespread community diseases like tuberculosis (TB) to proactively reach patients across India.
♦ It ensures access to Covihalt through its strong distribution network and field force.
♦ Previously, on August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name FluGuard for the treatment of mild to moderate cases of COVID- 19, at Rs.35 per tablet in India. Shares of Lupin were trading 0.32% higher at Rs.943.70 apiece on BSE.



source https://naukri.sarkari-exam.in/lupin-launched-coronavirus-drug-favipiravir-in-india-at-rs-49-per-tablet/
Download our All Government Jobs Android app to get updates on your mobile.

Recent Posts

Register Your Email